Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by chipmuki1234567on Mar 19, 2018 8:43pm

213 Views

Post# 27743494

RE:RE:Message from IR - news tomorrow AM

What is with the drama of halting... if you were going to release in the after hours or before open... just do that! JEEZZ... what is it? there was an issue? Study was bad... not sure the impact on stock price.... release the news and it will hit 0.06 and then management can "sell" citagenix... that's why should have focused on citagenix to begin with.. the $0.42 per share would be sustainable... lol to the "ATB-346 and $7.50 a share" dream people were having around here... JEEZZZ

Bullboard Posts

BlackBerry partners with Avathon to enhance critical event management with AI